CTOs on the Move

Envisionier medical technologies Inc

www.envisionier.com

 
Envisionier medical technologies Inc is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Jackson Healthcare

Jackson Healthcare is built on a simple idea — that talented professionals with a shared purpose can improve the lives of patients, families and communities. Headquartered in Alpharetta, Georgia, the company has risen to a place of prominence among the largest healthcare staffing and technology companies in the U.S. It currently serves more than seven million patients in over 1,300 healthcare facilities. In addition to serving health systems and providers, Jackson champions local, national and international charitable work. It founded and sponsors the Hospital Charitable Service Awards, which honors programs that set new standards for health and wellness in their communities through education, access and delivery. Atlanta Business Chronicle named Jackson Healthcare the city’s “Best Place to Work” in 2014, 2015, and 2016 and “Healthiest Large Company” in 2015.

GlobalTox

GlobalTox is a Guelph, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Predictive Physiology and Medicine (PPM)

Predictive Physiology and Medicine (PPM) is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NCM Publishers

NCM Publishers is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.